Introduction
Despite earlier diagnosis of prostate cancer and improved treatment modalities, there still exists a signi®cant risk of disease recurrence after therapy. In part this is due to clinical understaging of the cancer, which occurs in up to 50% of patients undergoing radical prostatectomy. 1 A recent analysis of patients enrolled in a disease registry of prostate cancer patients demonstrated that 22% of patients who received initial treatment with radical prostatectomy, radiation therapy, or cryotherapy required a second form of prostate cancer treatment within 3 y of initial therapy. 2 The majority of these treatments were administered in a therapeutic (nonadjuvant) fashion for apparent evidence of disease recurrence. Patients managed with radical prostatectomy had the lowest rate of second cancer treatment. Similar results have been reported by others, with at least 16 ± 35% of radical prostatectomy patients and 24% of radiotherapy patients receiving second cancer treatments within 5 y of primary treatment. 3 ± 5 Currently, failure of therapy is most often manifest solely by a rising prostate-speci®c antigen (PSA) level. Moul estimated that over 50 000 men have PSAonly recurrence after de®nitive treatment. 6 However, there are no adequate studies comparing outcomes of these secondary treatments, and the speci®c indications and optimal timing for additional therapy are equally unde®ned. Herein, we discuss the various treatment options with de®nitive, curative intent in patients whose cancers recur locally after radical prostatectomy and radiation therapy.
Risk factors for recurrence
Multiple studies have examined predictors of recurrence after de®nitive treatment for prostate cancer. Most of this data is derived from analysis of outcomes of patients treated by radical prostatectomy (Table 1) . Pre-treatment clinical features which correlate with prognosis include Tstage, biopsy Gleason score, and serum PSA level. 21 As one would expect, higher stage, the presence of Gleason pattern 4 or greater, or a Gleason sum greater than 7, and PSA levels exceeding 10 ng/mL are associated with an increased risk of progression after surgery. These elements have been combined in order to more accurately predict tumor extent, or pathological stage, and therefore prognosis; such probability tables and multivariate models have been based on a larger number of men who have undergone radical prostatectomy. 22 ± 24 Pathological criteria which are independent factors include tumor grade, surgical margin status, and the presence of extracapsular disease, seminal vesicle invasion, or involvement of pelvic lymph nodes (ie pathological stage greater than T2N0M0). 25 Similarly, in patients receiving radiation therapy, risks of recurrence are associated with pretreatment serum PSA, tumor grade, and clinical stage. In addition, PSA nadir following treatment predicts risk for treatment failure. 26 Thus, multiple predictors are available to help identify patients receiving de®nitive therapy for localized prostate cancer who are at increased risk for disease recurrence.
Identifying recurrence and its site
Prostate-speci®c antigen PSA is a powerful tool in the monitoring of patients after de®nitive treatment of clinically localized prostate cancer. Typically, biochemical failure precedes clinical disease by 6 to 48 months. 27 Pound et al characterized disease progression after PSA elevation in patients undergoing radical prostatectomy. Actuarial time to metastases was 8 y from the time of PSA failure and was predicted by time to biochemical failure, Gleason score, and PSA doubling time. 28 The serum PSA of patients after radical prostatectomy should fall to undetectable levels and initial testing should begin at 2 ± 3 months. Serial PSA measurements provide the most reliable method in detecting recurrence, as tumor progression rarely occurs in the absence of PSA elevation. Likewise, PSA is used as an endpoint in monitoring outcomes after radiotherapy. In these cases, however, PSA falls to low but often detectable levels and the PSA response to treatment is unpredictable. 29 As a result, de®nitions of treatment success and failure are variable and no consensus exists. Recent recommendation from the American Society of Therapeutic Radiology and Oncology (ASTRO) de®ne recurrence after radiotherapy as three consecutive rises in serum PSA independent of PSA nadir. 30 Only a single study has validated this de®nition by correlation with clinical outcomes. 31 Critz et al propose a PSA nadir of 0.5 ng/mL or more as the endpoint for brachytherapy treatment failure, demonstrating signi®cant 5 and 10-year disease-free survival rates in those with nadir PSA values less than 0.5 ng/mL. 32, 33 However, the prognostic value of this nadir depends on most men achieving a nadir of 0.2 ng/mL or less. 34 Time to reach PSA nadir varies with treatment modality. PSA nadir is typically achieved within 6 weeks after radical prostatectomy. Following radiation therapy, time to PSA nadir ranges from 8 to 18 months and even longer with brachytherapy. Ragde et al reported an average of 42 months to PSA nadir in a series of 152 patients receiving brachytherapy. 35 Patterns of PSA failure, such as time to failure, nadir PSA reached, time to nadir PSA level, and PSA velocity, are current methods to further evaluate for treatment failure. 32, 33, 36, 37 Another confounding factor in patients treated with radiation therapy is the concomitant use of androgen deprivation. No standard regimens or recommendations exist to address the optimal timing and duration of neoadjuvant and adjuvant hormonal therapy, resulting in dif®culty assessing treatment success, degree of recurrence, and ef®cacy (ie disease-speci®c survival) of salvage therapy. Thus, despite the wide-spread use of PSA to monitor disease activity after radiotherapy, controversy exists regarding exact de®nitions of treatment failure. In addition, it is important to keep in mind that most studies use PSA failure as a surrogate endpoint for cancer speci®c survival. While PSA may be a sensitive indicator of recurrent or residual disease, it may not accurately re¯ect the more relevant outcome of survival. 38 Distinguishing between local recurrence and distant failure is crucial in subsequent treatment decisions ( Figure 1 ). Physical examination of the prostate or surgical bed by digital ± rectal examination is neither sensitive nor speci®c in detection or localization of low-volume disease recurrence because of irradiated and postsurgical changes in the prostatic fossa. Changes in serial examinations over time, however, may help to detect local disease. 39 More recently, the need for anastoamotic biopsy has been questioned. Preliminary data from our patients receiving radiotherapy after prostatectomy show no differences in outcomes between those treated for biochemical failure alone and those treated for biopsy proven recurrence, suggesting that biopsy may not be necessary to de®ne patients most appropriate for salvage therapy. 40 PSA kinetics, in conjunction with pathological stage and Gleason grade, may provide the best means of identifying the location of tumor failure. Patients with low-grade disease generally have local recurrence, while those with seminal vesicle invasion or positive lymph nodes are more likely to fail distantly. PSA velocitỳ 0.75 ng/mL/y was observed in 94% of patients with local recurrence. 41 Conversely, over 50% of men with metastatic disease had a PSA velocity b0.75 ng/mL/y. In the same study, earlier postoperative elevations in PSA, within 2 y, were associated with distant disease. Clearly, PSA doubling time less than 6 months suggest distant disease. Trapasso et al described a median PSA doubling time of 4.3 months in patients ultimately progressing with distant failure, while those patients with clinically detected local failure or biochemical failure only had a PSA doubling time of 11.7 months. 42 Shorter PSA doubling times also predict increased risk for and shorter time to the appearance of clinical disease. 43 
Imaging
Imaging studies complement clinical and pathological information in localizing primary treatment failure. These modalities include bone scan, pelvic computed tomography (CT) and magnetic resonance imaging (MRI), positron emission tomography (PET), and singlephoton-emission computerized-tomography (SPECT). Higher tumor Gleason grade 7, 8, 15, 17 Positive surgical margin 7, 15, 18, 19 DNA ploidy 20 Most patients with evidence of disease recurrence undergo both bone scan and CT; however, the utility of these tests is unclear in patients with PSA-only progression. Oesterling suggested that radionucleotide bone scintigraphy is not cost-effective in those with minimal PSA elevation after prostatectomy. 44 Cher et al reported that bone scans are rarely positive (5%) until PSA reaches 30 ± 40 ng/mL; most patients who fail are detected at signi®cantly lower PSA levels. 45 Bone scans are most useful in patients with rapidly rising PSA (5 ng/mL/ month) or new skeletal symptoms. Likewise, crosssectional imaging to detect local recurrence or lymphadenopathy is fairly insensitive (60% and 30 ± 80%, respectively) and plays a greater role in men with higher PSA elevations and shorter PSA doubling time. 46, 47 As technology evolves in high resolution scanners, MRI, and magnetic resonance spectroscopy, so will their role in visualizing local and distant recurrence.
PET is not well-characterized in prostate cancer. Imaging takes advantage of differential cellular uptake and metabolism of a radiolabeled compound, such as the glucose analogue 18-¯uoro-2-deoxyglucose (FDG). 48 Theoretically the increased positron emission by tumor cells is detected and allows localization. Early studies report sensitivity and speci®city of 75% and 67%, respectively, in detecting lymph node metastases, although the utility of PET in recurrent prostate cancer especially after radiotherapy and cryotherapy is unclear. 49 The capromab penditide scan is based on a murine monoclonal antibody, recognizing prostate speci®c membrane antigen, conjugated to a linker-chelator and the radioisotope 111 indium. 50 Early data do not indicate a clear role for the capromab penditide immunoscintography, but it appears to detect prostatic fossa recurrence with reasonable accuracy. 51 Kahn et al reported on SPECT ®ndings and ability to predict response to salvage radiotherapy in 32 patients. 52 Seventy per cent of those patients with a normal scan or evidence of only local disease had a durable, complete response to radiotherapy while only 22% with capromab penditide ®ndings outside the prostatic fossa responded.
Recurrence after radical prostatectomy
Despite earlier diagnosis, improved patient selection, and evolution in surgical technique, as many as 35 ± 50% of patients undergoing radical prostatectomy develop biochemical recurrence after treatment. Up to half of these men have local recurrence with the remainder having distant disease alone or combined local and distant failure. 53 Therefore, it is important to de®ne the role of regional therapy in patients after radical prostatectomy who may potentially bene®t from further treatment.
Treatment of biochemical disease recurrence with radiation can often result in an undetectable PSA. In general, freedom from biochemical recurrence has been reported in 30 ± 65% of men following therapeutic, or salvage, radiotherapy (Table 2 ). 54 ± 63 Schild et al reported an overall 50% disease-free survival at 3 y; however, 78% of those patients with a pre-radiation PSA`1.0 ng/mL Figure 1 Algorithm for evaluation, diagnosis, and treatment of recurrent prostate cancer. RP radical prostatectomy, RT radiotherapy, PSA prostate speci®c antigen.
Local therapy for PSA recurrence MV Meng and PR Carroll were disease-free, while only 18% of men with PSA b1.0 ng/mL remained disease-free. 54 Forman et al also reported improved disease-free survival in patients with lower pre-radiation PSA (`2.0 ng/mL). 59 More recently, in a cohort of 166 patients treated with radiotherapy after prostatectomy, 46% were free of biochemical relapse at 5 y of follow-up. 60 Multivariate analysis identi®ed pathological stage, tumor grade, and pre-radiation PSA as independent factors associated with PSA relapse. Other investigators have reported no differences between adjuvant and therapeutic radiotherapy in patients with initially undetectable PSA after surgery. 64 Similarly, Coetzee et al noted a more durable response to radiation in men who failed after an initial undetectable PSA when compared to men with a persistently detectable PSA (66% at 40 months vs 20% at 12 months, respectively). 57 We recently evaluated our experience with radiation following radical prostatectomy in 105 patients at the University of California San Francisco. 40 The overall 5-y disease-free survival rate was 43%, with failure after radiation de®ned as PSAb0.2 ng/mL. Outcomes were equivalent in those men receiving adjuvant and salvage radiotherapy when therapeutic radiation was initiated with a low serum PSA (`1.0 ng/mL) ( Figure 2 ). There were no differences between the two groups with respect to pre-prostatectomy PSA, tumor grade, or pathological stage. Our data, as well as that from Vicini et al, also demonstrate the indication for radiotherapy (adjuvant vs therapeutic) as an independent prognostic factor associated with biochemical control. 63 However, no other clinical, pathological, or treatment-related factors were associated with 5-y outcome in their patients. Cadeddu et al. present more pessimistic data. 65 Only 21% of men had an undetectable PSA for over 2 y after therapeutic radiation following prostatectomy. No patients with a Gleason score of 9 or greater, positive seminal vesicles, or positive lymph nodes had undetectable PSA levels for more than 2 y. Finally, early treatment at lower PSA or isolated PSA elevation without documented local recurrence did not predict a favorable response to therapy. Thus, while it appears that adjuvant radiotherapy is a viable option in patients at higher risk for local recurrence, radiation may be utilized with ef®cacy in a therapeutic fashion when tumor volume, as re¯ected by serum PSA, is low. Patients most likely to bene®t from salvage radiation after prostatectomy include those with low to moderate grade tumors with an undetectable post-operative PSA that rises more than one year later. The exact timing of radiation has yet to be determined, although a PSA cutpoint of 2.0 ng/mL currently appears reasonable. The recent ASTRO consensus panel recommendations regarding salvage radiotherapy include a dose of at least 6400 cGy given when PSA is less than 1.5 ng/mL. 66 Other forms of treatment for locally recurrent disease after radical prostatectomy have been reported but are not well characterized. These include brachytherapy and cryosurgical ablation. Kotrouvelis et al treated ®ve patients with salvage brachytherapy after prostatectomy with acceptable morbidity and results. 67 At UCSF, we have treated three cases of local recurrence after prostatectomy with cryoablation; one patient has had an undetectable PSA for 3 y. Another had salvage brachytherapy after prostatectomy, and 18 months after the procedure his PSA is 0.03 ng/mL. However, further studies are required before their routine use after radical prostatectomy can be recommended.
Recurrence after radiation therapy
Radiation therapy, either external beam or brachytherapy, is used with greater frequency for organ-con®ned cancers. 68 A certain percentage of patients receiving radiation will fail locally due to either inadequate localization of the target, inadequate dose, or radiation resistance. Therefore, issues of detection and localization of recurrence after radiation and subsequent treatment options are important to elucidate.
As discussed, various de®nitions of PSA failure after radiation have been used. Nevertheless, any rising PSA level after radiation therapy may signal active, residual disease. An exception may be those who have been treated with neoadjuvant hormonal therapy, where androgen levels and PSA may rise after ceasing androgen deprivation. In addition, an interesting phenomenon has been noted in about one third of patients who receive brachytherapy, but not other forms of radiation. A selflimited, temporary rise in serum PSA often occurs 12 ± 18 months after the procedure; this benign PSA¯are is unrelated to tumor progression. 35 As many as one-third of patients may demonstrate rising PSA at 3 y and as many as half may fail clinically within 5 ± 7 y. 69 ± 71 Recurrence rates may have decreased with the use of techniques which target the prostate better and allow for delivery of higher doses. In those patients with recurrent or persistent localized disease, the curative options traditionally included salvage prostatectomy or cryoablation. Most commonly, however, androgen ablation was instituted with post-irradiation recurrence. We found that androgen deprivation is the most common form (88%) of secondary treatment after radiotherapy, suggesting limited curative options for those patients currently failing initial radiation.
Salvage prostatectomy after radiotherapy has been approached cautiously in the past. It is often technically dif®cult but has been demonstrated to be feasible with acceptable morbidity and cure rates. Overall, cancerspeci®c survival and disease-free rates have ranged from 70 to 90% and 30 to 50% at 8 ± 10 y, respectively. 72 ± 74 Pathologically organ-con®ned disease is found in 20 ± 50% of cases and is an important prognostic factor. Te®lli et al reported that all patients with organcon®ned disease were disease free at 34 months. 75 Amling et al reported a 10-year disease free survival of 43% in 108 patients, similar to results from Rogers et al and Moul et al. 74, 76, 77 Both DNA ploidy and preoperative serum PSA were signi®cant predictors of outcome following surgery. Another study also reported radical prostatectomy Gleason score as an independent predictor of cancer-speci®c survival. 78 Other factors in¯uencing outcomes of salvage prostatectomy include pre-radiation clinical stage and preoperative PSA. 79 Data suggest that PSA levels 10 ng/mL prior to surgery may predict pathologically localized disease and reduced recurrence. In general, salvage prostatectomy after radiation should be reserved for men with low comorbidity and a 10-y life expectancy in whom recurrence is not locally advanced. Parameters guiding the decision include Gleason sum less than 7, PSA`10 ng/mL, and clinical stage T2 or less at the time of both radiation and surgery. However, accurate presurgical staging is often dif®cult after radiation and may make appropriate patient selection dif®cult.
Interest in both primary and salvage cryosurgical ablation of the prostate has re-emerged with technical innovations and the desire for minimally-invasive procedures. High-resolution transrectal ultrasound allows precise placement of the probes and real-time visualization of the freezing process. In addition, freezing may cause greater tumor destruction of a heterogeneous, radioresistant cell population, even outside the prostate in adjacent tissue, when compared to other modalities. Reported results have been modest with the largest series of patients treated at MD Anderson Cancer Center. 80 Seventy-seven per cent of patients had negative sextant biopsies 6 months after cryoablation, but only 45 or 150 patients (31%) had persistently undetectable PSA with a mean follow-up for 13.5 months. A double freeze ± thaw cycle appeared to be more effective than a single cycle in reducing both positive post-treatment biopsy and biochemical failure rates. Bales et al noted only a 9% diseasefree rate after salvage cryotherapy. 81 The recent report from Columbia University found a 66% PSA-free survival in 43 patients at 12 months; PSA nadir (b0.1 ng/mL) was the only independent predictor of biochemical recurrence. 82 PSA characteristics in monitoring outcome following cryotherapy, either primary or salvage, are not well de®ned. Early evidence suggests that PSA nadir (`0.5 ng/mL) is currently the best prognostic indicator of biochemical and biopsy proved failure. Furthermore, it was noted that even small¯uctuations in PSA may signify subsequent biochemical failure. 83 Other variables, such as initial clinical stage, number of probes, and operator experience, may play a role in salvage outcomes.
Salvage brachytherapy after primary radiotherapy has been proposed as a promising treatment modality. 84 In the past, concerns centered on the risk of injury to the urethra, bladder, and rectum with additional radiation as well as the questionable biological response in a tumor with possible radioresistant elements, given failure of standard external beam radiotherapy. Further investigation is warranted given improvements in treatment planning and delivery methods, as well as the documented morbidity of alternatives (ie, prostatectomy and cryoablation). Grado et al followed 49 patients treated with brachytherapy after biopsy-proven, primary radiotherapy failure. 84 Actuarial biochemical-free survival was 34% at 5 y and was associated with a post-salvage PSA nadir below 0.5 ng/mL. Local disease control was 98%. These results are encouraging, especially given the treatment population. The median age was 73.3 y and 71% had locally advanced disease at initial presentation; 90% of the cancers were moderately to poorly differentiated on prebrachytherapy biopsies. Complications were similar to those patients undergoing primary brachytherapy and much lower than for salvage prostatectomy and cryotherapy. Beyer reported a comparable 5-year actuarial freedom from relapse rate (53%) which was associated with tumor grade and pre-brachytherapy PSA, but neither factor reached statistical signi®cance due to the small number of patients. 85 Innovative forms of therapy are being developed which may play a role in salvage therapy. Both high intensity focused ultrasound (HIFU) and radiofrequency interstitial ablation are being studied and appear to have promise in local control of prostate cancer. 86 ± 88 In preliminary studies, primary HIFU achieved local control in 60 ± 80% of patients. 89 Radiofrequency ablation was able to produce predictable lesions of in vivo prostates prior to radical prostatectomy.
Morbidity from secondary treatment
In evaluating additional treatments for prostate cancer recurrence, both local and distant, factors other than PSAfree or overall survival must be considered. All modalities, including salvage surgery, radiation, cryotherapy, and even traditional hormonal therapy, have signi®cant side effects and morbidity. Nevertheless, few studies carefully address these points. Te®lli et al examined quality of life in 68 men undergoing salvage procedures. 90 They reported signi®cantly worse outcomes in urinary continence and physical well-being after salvage prostatectomy, but similar satisfaction with respect to quality of life and potency compared to salvage radiotherapy. A study of salvage cryotherapy has recently been published. 91 The data support the need for urethral warming with respect to several aspects of quality of life and the authors conclude that salvage cryotherapy is not superior to salvage prostatectomy when considering morbidity. Patients should be made aware of these issues and the decision-making process should weigh these factors against potential bene®ts in prognosis. Moreover, additional studies are necessary to clarify questions of morbidity and quality of life in secondary treatments for recurrent prostate cancer.
Conclusions
Recurrence after de®nitive treatment for prostate cancer is a signi®cant problem. Inadequate studies exist to determine the optimal diagnostic and treatment strategies following either radical prostatectomy or radiation therapy where there is evidence of local disease. Limited curative options are available in many situations. We await the development of more ef®cacious and less morbid treatment options.
Promising areas of research include molecular characterization and earlier detection of prostate cancer relapse.
Pathological and immunohistochemical markers may add information to determine prognosis. It remains to be determined if genetic markers can predict disease recurrence or metastatic potential. If found, this information could direct the type and timing of additional treatments. Moreover, it may be recognized that not all patients who fail initial therapy as evidenced by biochemical relapse will suffer disease-speci®c morbidity or mortality. Discrimination of such patients would spare them the inconvenience, cost, and morbidity of complex testing and/or treatment. Earlier determination of PSA failure and prompt institution of salvage therapy may be possible with the ultrasensitive PSA assay. The lead time may increase the ef®cacy of second treatments such as radiotherapy after prostatectomy by minimizing tumor burden. Finally, many patients fail both primary and salvage therapy because of undetected metastatic, or micrometastatic, disease. Development of a systemic treatment may address this issue by affecting both local and distant prostate cancer cells. New approaches currently undergoing evaluation, such as antiangiogenesis agents or gene therapy, may revolutionize therapy of prostate cancer.
